ArtVentive EOS™ Device featured at SIR 2017 Conference in Washington, D.C.

ArtVentive EOS™ Device featured at SIR 2017 Conference in Washington, D.C.

 

Source: ArtVentive Medical Group, Inc.

 

Carlsbad, CA / March 5, 2017 / ArtVentive Medical Group, Inc. announced today that the company’s flagship occlusion device, the ArtVentive EOS™, Endoluminal Occlusion System is being featured at the Annual Society of Interventional Radiology Global Scientific Meeting in Washington, D.C., March 4-9.

 

The EOS™ device, now approved by the FDA, immediately halts blood and fluid flow when deployed in veins, arteries and tubes in the human body. The EOS™ is a patented device; utilized by interventional radiologists, vascular surgeons and interventional cardiologists to reduce to procedural time, radiation exposure and material costs.

 

Leon Rudakov, PhD, President and CTO, commented, “SIR is a global meeting where world leaders in interventional radiology gather to discuss new technologies and procedures. It is the ideal forum to make physicians aware of the EOS™ and its potential for routine utilization in cases where use of vascular plugs and embolization coils is appropriate. We are working in a very competitive space and therefore need to show true advantages and clinical benefits over traditional methods and devices”.

 

About ArtVentive Medical Group, Inc.

 

ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is an innovative, multi-faceted medical device company focused on developing, manufacturing and marketing globally a family of devices featuring the ArtVentive EOS™, Endoluminal Occlusion System.

 

The EOS™ device is a catheter-based, self-expandable, ePTFE covered embolization plug that creates immediate occlusion. It has potential to reduce procedural time, radiation exposure and material costs.

 

The EOS™ device is indicated for use in arterial and venous applications ranging from 3mm to 11mm in diameter. A unique two-step controlled deployment allows for precise placement of the EOS™ device at the target location. Initial clinical evidence shows 100% sustained vessel occlusion with no migration.

 

Learn more about EOS™ device by visiting booth 560 at SIR and www.artventivemedical.com

 

For More Information:

ArtVentive Medical Group, Inc.

Tyson Brill, Director of Sales

Telephone: 844-622-5833

Email: tysonbrill@artventivemedical.com